Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use.

Association between high CD73 expression and worse disease-free survival (DFS) almost reached significance compared with those with low CD73 expression (p-value = 0.06, HR = 1.66, 95% CI = 0.982–2.8) in the control arm but not in the zoledronic acid arm (Fig. 2 C, D; Table 3 ).

also in 62 other papers